Please login to the form below

Not currently logged in
Email:
Password:

New PR hires at Pfizer and Cephalon

Pfizer has hired former GE executive Peter O'Toole as VP, communications in its Washington, DC office, while Cephalon has hired Pfizer's Natalie de Vane as senior director, corporate communications and public affairs

Pfizer has hired former General Electric (GE) executive Peter O'Toole to serve as vice president, communications in its Washington, DC office, while Cephalon has brought Pfizer's Natalie de Vane on board in the position of senior director, corporate communications and public affairs.

O'Toole was previously director, executive communications at GE, a position that he held for about 16 months. Before being promoted to that post, he served as GE's director, public relations, public affairs for nearly five years. He has also worked on the agency side, spending more than four years at Burson-Marstellar, and was a speechwriter to the Secretary of Energy and Special Projects Officer at the US Department of Energy.

O'Toole's post at Pfizer is a newly created position that gives him responsibility for policy, external affairs, and communications.

De Vane recently joined Cephalon from Pfizer, where she was vice president, corporate affairs at Wyeth Nutrition, which became part of Pfizer through the 2009 merger with Wyeth. She was promoted to that post about two years ago, after working in corporate communications for Wyeth for 12 years.

At Cephalon, de Vane's responsibilities include external and internal communications, media relations and corporate brand management. She reports to Fritz Bittenbender, the company's VP of public affairs.

14th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics